An engineering strategy to target activated EGFR with CAR T cells
EGFR is often found to be constitutively activated in human cancer. Dobersberger et al. develop an engineering strategy for the generation of binding domains specifically recognizing ligand-activated EGFR. Incorporation of these binders into CAR molecules allows for specific targeting of the activated state of EGFR with CAR T cells.